Results 1 to 10 of about 17,969 (166)

Expression of gastrin and cholecystokinin B receptor in Lateolabrax maculatus

Aquaculture and Fisheries, 2023
Gastrin (gas) is a peptide hormone that stimulates gastric acid secretion by gastric parietal cells and stimulates gastric motility. The cholecystokinin B receptor (cckbr) can act as a receptor for gastrin, conveying regulatory information on gastrin ...
Tingwen Cui, Jiaqi Wang, Zhongjun Hu, Xiaowu Chen   +3 more
doaj   +2 more sources

Effects of Proglumide with Chemotherapy on the Pancreatic Tumor Microenvironment: Phase 1 PROGEM Trial [PDF]

Pharmaceutics
Background: The primary aim of this Phase 1 clinical trial was to study the safety and dose of a cholecystokinin receptor antagonist, proglumide, in combination with gemcitabine/nab-paclitaxel (GEM-NAB-P) in patients with metastatic pancreatic cancer ...
Jill P. Smith, Gakiza C. Nkulikiyimana, Hong Cao, Wenqiang Chen, Bhaskar Kallakury, John Kwagyan, Anju Duttargi, Benjamin A. Weinberg   +7 more
doaj   +2 more sources

Cholecystokinin B receptor agonists alleviates anterograde amnesia in cholecystokinin-deficient and aged Alzheimer's disease mice

Alzheimer’s Research & Therapy
Background As one major symptom of Alzheimer’s disease (AD), anterograde amnesia describes patients with an inability in new memory formation. The crucial role of the entorhinal cortex in forming new memories has been well established, and the ...
Nan Zhang, Yixuan Sui, Peter Jendrichovsky, Hemin Feng, Heng Shi, Xu Zhang, Shenghui Xu, Wenjian Sun, Huatang Zhang, Xi Chen, Micky D. Tortorella, Jufang He   +11 more
doaj   +3 more sources

Single-chain Fragment variable antibody targeting cholecystokinin-B receptor for pain reduction

Neurobiology of Pain, 2021
The cholecystokinin B receptor and its neuropeptide ligand are upregulated in chronic neuropathic pain models. Single-chain Fragment variable antibodies were generated as preferred non-opioid targeting therapy blocking the cholecystokinin B receptor to ...
K.N. Westlund, M.A. Montera, A.E. Goins, S.R.A. Alles, M. Afaghpour-Becklund, R. Bartel, R. Durvasula, A. Kunamneni   +7 more
doaj   +1 more source

25380 Cholecystokinin-B Receptor -Mediates Growth of Hepatocellular Carcinoma

Journal of Clinical and Translational Science, 2021
IMPACT: Cholecystokinin-B Receptor -Mediates Growth of Hepatocellular Carcinoma with the use proglumide. Proglumide is a non-selective antagonistic drug therefore, strategies that block signaling at the CCK-BR may provide to be a novel therapeutic option
Martha Dee Gay, Anita Safronenka, Hong Cao, Robin Tucker, Narayan Shivapurkar, Jill P. Smith   +5 more
doaj   +1 more source

CCK1R2R-/- ameliorates myocardial damage caused by unpredictable stress via altering fatty acid metabolism

Stress, 2023
The heart is the main organ of the circulatory system and requires fatty acids to maintain its activity. Stress is a contributor to aggravating cardiovascular diseases and even death, and exacerbates the abnormal lipid metabolism.
Zhi-Hua Zhang, Chen-Teng Yang, Xiao-Rui Su, Ya-Ping Li, Xiao-Jing Zhang, Song-Jun Wang, Bin Cong   +6 more
doaj   +1 more source

Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo

Pharmaceuticals, 2022
In order to enable 18F- and 177Lu-labelling within the same molecule, we introduced a silicon-based fluoride acceptor (SiFA) into the hexa-D-glutamate chain of DOTA-PP-F11N.
Nadine Holzleitner, Thomas Günther, Roswitha Beck, Constantin Lapa, Hans-Jürgen Wester   +4 more
doaj   +1 more source

Cholecystokinin-B Receptor-Targeted Nanoparticle for Imaging and Detection of Precancerous Lesions in the Pancreas

Biomolecules, 2021
Survival from pancreatic cancer remains extremely poor, in part because this malignancy is not diagnosed in the early stages, and precancerous pancreatic intraepithelial neoplasia (PanIN) lesions are not seen on routine radiographic imaging.
Jill P. Smith, Hong Cao, Elijah F. Edmondson, Siva Sai Krishna Dasa, Stephan T. Stern   +4 more
doaj   +1 more source

Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs

EJNMMI Research, 2023
Background Over the last years, several strategies have been reported to improve the metabolic stability of minigastrin analogs. However, currently applied compounds still reveal limited in vitro and in vivo stability. We thus performed a glycine scan at
Nadine Holzleitner, Thomas Günther, Amira Daoud-Gadieh, Constantin Lapa, Hans-Jürgen Wester   +4 more
doaj   +1 more source

Development of the First ¹⁸F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety

Pharmaceutics, 2023
In order to optimize elevated kidney retention of previously reported minigastrin derivatives, we substituted (R)-DOTAGA by DOTA in (R)-DOTAGA-rhCCK-16/-18.
Thomas Günther, Nadine Holzleitner, Daniel Di Carlo, Nicole Urtz-Urban, Constantin Lapa, Hans-Jürgen Wester   +5 more
doaj   +1 more source